Telisotuzumab vedotin

N/A

Report date: 2025/06/11 20:01:15

Base Information

Drug NameTelisotuzumab vedotin
Drug Alias NameTeliso-Vtelisotuzumab vedotin-tllvEMRELISABT-399ABBV-399
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker > VC linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > MMAE payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionHepatocyte growth factor receptor inhibitorsMicrotubule proteins inhibitors
TargetsHepatocyte growth factor receptorMicrotubule proteins
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell Lung
Global Approved IndicationsCarcinoma, Non-Small-Cell Lung
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2025/05/14
Country/TerritoryCzechiaBelgiumBulgaria +[40] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesAbbvie Inc
China Registration ClassN/A

Develop Information

Active CompaniesAbbvie IncAbbvie Pharmaceutical Trading（Shanghai）Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell Lung
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG